Can a monthly shot tame Sky-High cholesterol in children?

NCT ID NCT07102511

First seen Jul 28, 2026 · Last updated Jul 29, 2026 · Updated 1 time

Summary

This trial tests whether a monthly injection of lerodalcibep can safely lower LDL cholesterol in children aged 6 to 17 with heterozygous familial hypercholesterolemia, an inherited condition that causes dangerously high cholesterol. Participants receive either the drug or a placebo injection every month for about six months, alongside their usual diet and cholesterol-lowering medications. The study measures changes in LDL levels at 12 and 24 weeks to see if the drug offers additional benefit.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
an experimental drug called lerodalcibep (Lerochol), given as a monthly injection
What this could lead to
If it works, this could offer a new monthly injection option to help children with inherited high cholesterol lower their LDL levels.
What could go wrong
This is a phase 3 trial, so earlier results are promising but not definitive. The drug may cause side effects or not work as well in younger patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FAMILIAL HYPERCHOLESTEROLEMIA - HETEROZYGOUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

familial hypercholesterolemia Hypercholesterolemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Ege Universitesi Tip Fakultesi

    Izmir, 35100, Turkey (Türkiye)

  • Iatros International

    Bloemfontein, Free State, South Africa

  • Lipid Clinic Hadassah Medical Center

    Jerusalem, Israel

  • Lipid Clinic Wits University

    Johannesburg, Gauteng, 2193, South Africa

  • Metabolic & Atherosclerosis Research Center

    Cincinnati, Ohio, 45227, United States

  • New Zealand Clinical Research

    Christchurch, 8011, New Zealand

  • The Lipid Clinic Oslo University Hospital

    Oslo, 0586, Norway

More trials for these conditions

Other studies related to the condition(s) this trial covers.